Anzeige
Mehr »
Samstag, 28.06.2025 - Börsentäglich über 12.000 News
Diese KI-Biotech-Aktie revolutioniert die Krebstherapie: Lernen Sie Rakovina Therapeutics kennen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2AHDP | ISIN: CH0308403085 | Ticker-Symbol: GEM
Frankfurt
27.06.25 | 08:02
0,039 Euro
+7,65 % +0,003
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
GENEURO SA Chart 1 Jahr
5-Tage-Chart
GENEURO SA 5-Tage-Chart
RealtimeGeldBriefZeit
0,0540,06213:03

Aktuelle News zur GENEURO Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
12.06.GeNeuro SA Announces the Opening of Receivership Proceedings for Its French Subsidiary GeNeuro Innovation SAS275Regulatory News: GeNeuro (Euronext Paris: CH0308403085 GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, announces that, at the company's...
► Artikel lesen
10.06.GeNeuro SA Announces an Extraordinary Shareholders' Meeting on June 30, 2025216Regulatory News: GeNeuro (Euronext Paris: CH0308403085 GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, announces that it will hold an...
► Artikel lesen
27.05.GeNeuro SA Announces Definitive Debt-Restructuring Moratorium326Regulatory News: GeNeuro (Euronext Paris: CH0308403085 GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, announces that the Geneva Court...
► Artikel lesen
12.05.GeNeuro SA Announces the Postponement of the Publication of the Company's 2024 Annual Results381Regulatory News: GeNeuro (Euronext Paris: CH0308403085 GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, announces the postponement of...
► Artikel lesen
28.01.GeNeuro SA Announces Renewal of Provisional Debt-Restructuring Moratorium540Regulatory News: GeNeuro (Euronext Paris: CH0308403085 GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, announces that the Geneva Court...
► Artikel lesen
06.12.24New Data Supporting a New Precision Medicine Approach for ALS Patients With GeNeuro's GNK-301 Presented at the 35th International Symposium on ALS/MND852Regulatory News: GeNeuro (Euronext Paris: CH0308403085 GNRO), a biopharmaceutical company focused on addressing the factors driving the progression of neurodegenerative and autoimmune diseases...
► Artikel lesen
30.09.24GeNeuro SA Obtains the Opening of Debt-Restructuring Proceedings580Regulatory News: GeNeuro (Euronext Paris: CH0308403085 GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, announces that the Geneva Court...
► Artikel lesen
19.09.24GeNeuro: New Data Presented at the ECTRIMS 2025 Congress in Copenhagen Shows That Temelimab Rescues the Neurodegenerative Effects of HERV-W in an MS Model563Regulatory News: GeNeuro (Euronext Paris: CH0308403085 GNRO), a biopharmaceutical company focused on addressing the factors driving the progression of neurodegenerative and autoimmune diseases...
► Artikel lesen
GENEURO Aktie jetzt für 0€ handeln
28.08.24XFRA GEM: WIEDERAUFNAHME/RESUMPTION415FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME...
► Artikel lesen
05.08.24XFRA GEM: AUSSETZUNG/SUSPENSION414DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILGENEURO SA SF-,05...
► Artikel lesen
15.07.24GeNeuro Announces That It Submits a Request for a Debt Moratorium to the Geneva Court of First Instance425Regulatory News: GeNeuro (Euronext Paris: CH0308403085 GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases such as multiple sclerosis (MS)...
► Artikel lesen
10.07.24GeNeuro SA: End of the Liquidity Contract With GILBERT DUPONT406Regulatory News: GeNeuro SA (Paris:GNRO) and GILBERT DUPONT have terminated the liquidity contract entered into on March 6, 2021. This termination took effect on June 30, 2024, after market...
► Artikel lesen
03.07.24Geneuro SA: Half-Yearly Report on the Liquidity Contract with Gilbert Dupont445Market: Euronext Paris ISIN code Mnemo: CH0308403085 GNRO Web site: www.geneuro.com Regulatory News: Pursuant to the liquidity contract entrusted by GENEURO SA (Paris:GNRO) to Gilbert Dupont...
► Artikel lesen
13 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1